Reference
Freeman ML, et al. Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma. 54th Annual Meeting of the American Society of Clinical Oncology : abstr. 9594, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_220221.html
Rights and permissions
About this article
Cite this article
Nivolumab good value as adjuvant therapy for resected melanoma. PharmacoEcon Outcomes News 806, 18 (2018). https://doi.org/10.1007/s40274-018-5061-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5061-5